



Frontiers in Flavivirus Vaccines

Guest Editors:

Dr. Sasha R. Azar

Department of Pathology,
University of Texas Medical
Branch, Galveston, TX 77555, USA

Dr. Carlos A. Sariol

Unit of Comparative Medicine,
School of Medicine, University of
Puerto Rico, San Juan 00936,
Puerto Rico

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editors

Dear Colleagues,

The past three decades have been characterized by an unprecedented emergence of various zoonotic viral agents. Of these, viruses within the *Flavivirus* genus of the family *Flaviviridae* are of particular concern to human health, as demonstrated by the global spread of West Nile virus, the explosive outbreaks of Zika in the Americas, and the enormous disease burden of the four dengue viruses. While vaccines for some *Flaviviruses* (YFV, JEV, TBEV) do exist, there are regional disparities in availability and usage. With the trend towards urbanization, deforestation, and global travel facilitating greater human-animal contact as well as the spread of invasive arthropod vectors beyond their original ranges, additional and novel *Flavivirus* vaccines, vaccine formulations, and strategies will be critical going forward. To that end, the present Special Issue will address advances in, as well as novel *Flavivirus* vaccines, vaccination strategies, vaccine formulations or technologies, and animal models describing correlates of protection.

Dr. Sasha R. Azar

Dr. Carlos A. Sariol

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)